RenovoRx (RNXT) investor relations material

Clinical landscape and unmet needs

• Pancreatic cancer treatment remains largely unchanged, with most patients requiring lifelong chemotherapy, which is often poorly tolerated due to significant toxicity and side effects.

• Only 10-15% of patients are eligible for surgery; the majority present with metastatic or locally advanced, unresectable disease.

• Quality of life and reduction of treatment toxicity are key priorities, especially for those unable to tolerate ongoing systemic chemotherapy.

TAMP platform and clinical data

• The TAMP platform delivers chemotherapy directly to the tumor using the RenovoCath device, achieving up to 100 times higher local drug concentration and significantly reducing systemic toxicity.

• Interim phase III TIGeR-PaC data show a 65% reduction in side effects and a trend toward improved survival, with patients living up to six months longer than with standard care.

• TAMP is increasingly used as a maintenance therapy after initial chemotherapy and radiation, offering a less toxic alternative for disease control.

Adoption and commercialization update

• Active treatment centers have grown from 4-5 to 21, with revenue climbing and a small sales team driving adoption.

• Economic incentives are strong: hospitals and physicians are reimbursed, and there are no significant financial barriers to adoption.

• The average sales cycle for new centers is 4-6 months, with local reps accelerating onboarding and expansion.